

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

[ ] Check this box if no longer  
subject to Section 16. Form 4 or  
Form 5 obligations may  
continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
<b>Bondurant William</b>		<b>CASTLIGHT HEALTH, INC. [ CSLT ]</b>		<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>Chief Financial Officer</b>	
(Last) (First) (Middle)		3. Date of Earliest Transaction (MM/DD/YYYY)			
<b>C/O CASTLIGHT HEALTH, INC., 150 SPEAR STREET, SUITE 400</b>		<b>2/16/2021</b>			
(Street)		4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)	
<b>SAN FRANCISCO, CA 94105</b>				<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class B Common Stock	2/16/2021		M		625	A	\$0.00	215944	D	
Class B Common Stock	2/16/2021		M		1250	A	\$0.00	217194	D	
Class B Common Stock	2/16/2021		M		1250	A	\$0.00	218444	D	
Class B Common Stock	2/16/2021		M		3125	A	\$0.00	221569	D	
Class B Common Stock	2/16/2021		M		2813	A	\$0.00	224382	D	
Class B Common Stock	2/16/2021		M		17606	A	\$0.00	241988	D	
Class B Common Stock	2/16/2021		M		18750	A	\$0.00	260738	D	
Class B Common Stock	2/17/2021		S(1)		19676	D	\$1.8944 (2)	241062	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units (RSU)	(3)	2/16/2021		M		625		(4)	(4)	Class B Common Stock	625	\$0.00	625	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		1250		(5)	(5)	Class B Common Stock	1250	\$0.00	2500	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		1250		(6)	(6)	Class B Common Stock	1250	\$0.00	7500	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		3125		(6)	(6)	Class B Common Stock	3125	\$0.00	18750	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		2813		(7)	(7)	Class B Common Stock	2813	\$0.00	22500	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		17606		(8)	(8)	Class B Common Stock	17606	\$0.00	193663	D	
Restricted Stock Units (RSU)	(3)	2/16/2021		M		18750		(9)	(9)	Class B Common Stock	18750	\$0.00	225000	D	

**Explanation of Responses:**

- (1) Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the RSUs. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
- (2) Represents the weighted average sales price per share. The shares sold at prices ranging from \$1.80 to \$2.02 shall be provided upon request to the staff of the

U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

- (3) Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration.
- (4) 1/4th of the RSUs vested on May 16, 2018 and the remainder will vest 1/16th quarterly over three years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
- (5) 1/4th of the RSUs vested on August 16, 2018, and the remainder will vest 1/16th quarterly over three years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
- (6) 1/16th of the RSUs vested on November 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
- (7) 1/16th of the RSUs vested on May 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
- (8) 1/16th of the RSUs vested on February 16, 2020, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
- (9) 1/16th of the RSUs vested on May 16, 2020 and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>Bondurant William</b> <b>C/O CASTLIGHT HEALTH, INC.</b> <b>150 SPEAR STREET, SUITE 400</b> <b>SAN FRANCISCO, CA 94105</b>			<b>Chief Financial Officer</b>	

**Signatures**

/s/ Mary Ahern, as attorney-in-fact

2/18/2021

--Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.